Cambridge, UK; April 8, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, today announced the appointment of Simon Sturge as its new CEO, effective May 1, 2019. Simon succeeds David Chiswell, who remains a scientific adviser to the Company.
“We are delighted that such an experienced leader as Simon will lead Kymab to its next stage of growth,” said Martin Nicklasson, Non-Executive Chair. “Led by Simon, Kymab will continue to progress its innovative portfolio of products through the clinic and to market, driving our strategy to…
Cambridge, UK, 08 April 2019: Metrion Biosciences (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Andrew Southan as Chief Executive Officer, with immediate effect. Dr Southan was previously the Company’s Chief Operating Officer.
Dr Southan joined Metrion as Head of Commercial Operations in October 2016, was promoted to Chief Operating Officer in April 2017, and joined the board as a director in March 2018. During this period the Company has made significant progress, developing innovative, high-quality assays…
Cambridge, UK, 03 April 2019: TTP plc (TTP), a leading independent technology and product development company, has announced today the formation of Cellular Highways Ltd. The new spin-out has been founded to commercialise TTP’s proprietary Vortex-Actuated Cell Sorting (VACS) technology, and fast-track development of a first commercial product, Highway 1™. TTP has invested £1.7m ($2.2m) in the spin-out, in addition to over £2m development funding to date. Highway 1 will be unveiled at CYTO, the 34th Congress of the International Society for Advancement of Cytometry, in Vancouver, 22-26 June…
Building on the success of 2018, LabKey will be holding two User Events in Europe in June 2019.
4th and 5th June: Basel Switzerland
6th June: London
The user events are designed to provide a fun and relaxed forum to learn more about what LabKey is and how we help over 500 research institutions around the world to eliminate and address their research data management challenges.
LabKey is a freely accessible, enterprise-quality, open source platform designed to manage, integrate, analyse and share research data for the global life sciences industry. With over 16 years of development and…
Lonza is to set up a virtual tenancy at Stevenage Bioscience Catalyst (SBC). Through this collaboration, Lonza’s scientific experts will establish a regular presence at SBC working with the Business Development team, joining a vibrant community for biotech growth and development.
Sarah Holland, Global Head of Licensing at Lonza commented: “Supporting innovation is a key focus for Lonza. Working closely with SBC gives us the opportunity to build strong relationships with other residents at the BioCatalyst. Interacting with other companies in this highly networked and innovative environment, in…
No, not an April Fools’ joke - BioBridge Ltd, the Cambridge-based independent life science innovation consultancy, was founded in 1989 and has been at the forefront of biotechnology and life science advances since then, from a ground-breaking report for Frost&Sullivan on biotechnology in animal breeding and production, via helping establish new approaches to xenogeneic therapies and biopharming, to current involvement in the latest green and blue biotechnology advances.
Dr Meredith Lloyd-Evans, founder and CEO of BioBridge Ltd, said “Since we started, we have worked with over 100 clients…
Cambridge, UK, 2nd April: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today confirmed that it has entered into a commercial agreement with Addenbrooke’s hospital, part of Cambridge University Hospitals NHS Foundation Trust, to provide PredictSURE IBD™ to clinicians and gastroenterologists in the UK and Ireland.
Under the agreement, the East Midlands and East of England Genomic Laboratory Hub based at Addenbrooke’s Hospital, will manage and facilitate the fulfilment of orders of PredictSURE…
Cambridge, UK, 01 April 2019: Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research and drug discovery company, announced today that it has completed a fully subscribed funding round on 14 March. Metrion will use the funds to support the broadening of its ion channel screening capabilities, and continued research into novel Kv1.3 inhibitors for the treatment of auto-immune conditions.
The new equity investment round was led by the recently launched o2h Ventures Therapeutics Fund, acting via Reyker Securities plc, and supported by existing shareholders…
Establishes New Clinical Advisory Board of Leading Oncology Experts
Cambridge, UK, 1 April 2019. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announces the appointment of Ian Smith, M.D., as Chief Medical Officer. Dr. Smith will assume responsibility for leading Artios’s overall preclinical and clinical development strategy, regulatory, and medical activities. He will work in tandem with and report directly to Niall Martin, Chief Executive Officer, and join the company’s executive leadership…